ClinicalTrials.gov
ClinicalTrials.gov Menu

Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB (SQ109EBA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01218217
Recruitment Status : Completed
First Posted : October 11, 2010
Last Update Posted : January 14, 2013
Sponsor:
Collaborators:
Sequella, Inc.
European and Developing Countries Clinical Trials Partnership (EDCTP)
German Federal Ministry of Education and Research
Quintiles, Inc.
CMed Technologies Inc.
PathCare
Parexel
Information provided by (Responsible Party):
Michael Hoelscher, Ludwig-Maximilians - University of Munich

Brief Summary:
SQ109 was developed with the aim of shortening TB treatment and providing new drugs for resistant TB. The drug has demonstrated efficacy in toxicology studies and an acceptable safety profile in first-in-man studies. The objective of this study is to evaluate the extended early bactericidal activity (EBA), safety, tolerability, and pharmacokinetics of several doses of SQ109 with or without Rifampicin (RIF) for 14 days in adults with newly diagnosed, uncomplicated, smear positive, pulmonary TB.

Condition or disease Intervention/treatment Phase
Tuberculosis, Pulmonary Drug: SQ109 Drug: Rifampicin Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2A Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of SQ109 in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis
Study Start Date : November 2010
Actual Primary Completion Date : September 2011
Actual Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis
Drug Information available for: Rifampin

Arm Intervention/treatment
Experimental: SQ109 75 mg
75 mg SQ109 monotherapy daily
Drug: SQ109
SQ109 150 mg tablet

Experimental: SQ109 150 mg
150 mg SQ109 daily
Drug: SQ109
SQ109 150 mg tablet

Experimental: SQ109 300 mg
300 mg SQ109 daily
Drug: SQ109
SQ109 150 mg tablet

Experimental: SQ109 150 mg + RIF
150 mg SQ109 + RIF standard dose daily
Drug: SQ109
SQ109 150 mg tablet

Drug: Rifampicin
Rifampicin 150 mg capsules

Experimental: SQ109 300 mg + RIF
300 mg SQ109 + RIF standard dose daily
Drug: SQ109
SQ109 150 mg tablet

Drug: Rifampicin
Rifampicin 150 mg capsules

Active Comparator: RIF Mono
Standard dose Rifampicin monotherapy daily
Drug: Rifampicin
Rifampicin 150 mg capsules




Primary Outcome Measures :
  1. The extended early bactericidal activity (EBA)of daily 75 mg, 150 mg, and 300 mg SQ109, and of daily 150 mg or 300 mg SQ109 with daily RIF standard dose in adults with newly diagnosed, uncomplicated, smear positive, pulmonary TB. [ Time Frame: Daily during first two weeks ]

Secondary Outcome Measures :
  1. The standard EBA (EBA 0-2) of each treatment group, as determined by the rate of change of log Colony Forming Units (logCFU) in sputum over the period Day 0-2 (linear, bi-linear or non-linear regression of logCFU over time). [ Time Frame: Day 0 - Day 2 ]
  2. Extended EBA (EBA 2-14) of each treatment group, as determined by the rate of change of logCFU in sputum over the periods Day 2-14 (linear, bi-linear or non-linear regression of logCFU over time). [ Time Frame: Days 2-14 ]
  3. The change in time to positivity (TTP) in the Mycobacterium Growth Indicator Tube (Bactec MGIT 960 system). [ Time Frame: Days 0-14 ]
  4. Pharmacokinetics [ Time Frame: Days 1,2,7,8,14,15 ]
  5. Proportion of subjects with serious adverse events and proportion of subjects who discontinue due to an adverse event in each experimental arm. [ Time Frame: Entire study period ]
    These will be presented as descriptive analyses, and no inferential tests will be carried out.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provide signed written informed consent for study participation, including HIV testing (if HIV serostatus is not known or the last documented negative is more than four weeks prior to enrolment).
  2. Be eighteen (18) to 64 (inclusive) years of age.
  3. Have a body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.
  4. Have newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB.
  5. Have a chest X-ray which, in the opinion of the Investigator, is compatible with TB.
  6. Is sputum positive on direct microscopy for acid-fast bacilli (at least 1+ on the IUATLD/WHO scale (Appendix 3).
  7. Is able to produce an adequate spot sputum sample, indicating an overnight sputum volume of at least 10 mL.
  8. Female patients of childbearing potential must have a negative serum pregnancy test, and consent to practice two effective methods of birth control when not abstaining from sexual intercourse, unless she and her partner(s) are surgically sterile or she is post-menopausal with no menses for the last 12 months. Preferably, contraceptive measures should be continued until completion of TB treatment, but at least until one month after last dose of IMP, unless she and her partner(s) are sterile (that is, women who have had a bilateral oophorectomy or hysterectomy or have been postmenopausal for at least 12 consecutive months).

    Two of the following methods may be used, but only one may be hormonal: tubal ligation, vaginal diaphragm, intrauterine device, condom, oral contraceptives, contraceptive implant, combined hormonal patch, combined injectable contraceptive or depot-medroxyprogesterone acetate, partner(s) has had a vasectomy.

  9. Male participants must agree to use an adequate method of contraception when not abstaining from sexual intercourse throughout participation in the trial and for 12 weeks after last dose, unless he has had bilateral orchidectomy.
  10. A Karnofsky score of at least 60 (requires occasional assistance but is able to care for most of his/her needs, see Appendix 5)

Exclusion Criteria:

  1. Poor general condition where any delay in treatment cannot be tolerated per discretion of Investigator.
  2. Treatment with any drug active against MTB within the 3 months prior to Visit 1 (this includes, but is not limited to INH, EMB, RIF, PZA, amikacin, cycloserine, rifabutin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, thioacetazone, capreomycin, fluoroquinolone, thioamides, metronidazole).
  3. Sputum isolate is resistant to RIF as detected by rapid assay from native sputum
  4. A history of allergy to the IMP or related substances.
  5. Clinically significant evidence of extrathoracic TB (miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis), as judged by the investigator.
  6. A history of previous TB.
  7. Evidence of serious lung conditions other than TB or uncontrolled obstructive bronchial disease.
  8. Laboratory parameters done at, or within 14 days prior to, screening:

    • Serum amino aspartate transferase (AST) and/or serum alanine aminotransferase (ALT) activity >3 times the upper limit of normal
    • Serum total bilirubin level >2.5 times the upper limit of normal
    • Serum creatinine level >2 times the upper limit of normal
    • Complete blood count with hemoglobin level <7.0 g/dL
    • Platelet count <50,000/mm3
    • Serum potassium <3.5 meq/L
  9. History, presence, or evidence of a neuropathy or epilepsy.
  10. Clinically relevant change s in the ECG such as atrioventricular (AV) block, prolongation of the QRS complex over 120 milliseconds, or of either the QTcF or QTcB interval over 450 milliseconds on the screening ECG.
  11. A history of, or current clinically relevant cardiovascular disorder such as myocardial infarction, heart failure, coronary heart disease, hypertension, arrhythmia, or tachyarrhythmia. Family history of sudden death of unknown or cardiac-related cause, or of prolonged QTc interval. Concomitant use of any drug known to prolong QTc interval (including amiodarone, bepridil chloroquine, chlorpromazine, cisapride, cisapride, clarithromycin, disopyramide dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, lumefantrine, mesoridazine, methadone, pentamidine, pimozide, procainamide, quinidine, sotalol, sparfloxacin, terfenadine, thioridazine).
  12. Diabetics using insulin.
  13. Evidence of clinically significant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or other abnormalities (other than the indication being studied).
  14. Any disease or condition in which the use of the standard TB drugs or any of their components is contraindicated, including but not limited to allergy to any TB drug, their components or to the IMPs.
  15. Any disease or condition in which any of the medicinal products listed in the section pertaining to prohibited medication (see 4.10.4) is used.
  16. Known or suspected, current or history of within the past 2 years, alcohol or drug abuse, that is, in the opinion of the investigator, sufficient to compromise the safety or cooperation of the patient. Opiates prescribed for cough relief are not counted as drug abuse.
  17. Prior administration of SQ109.
  18. Is pregnant, breast-feeding, or planning to conceive or father a child within one month of cessation of treatment.
  19. Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes (including xenobiotics, quinidine, tyramine, ketoconazole, testosterone, quinine, gestodene, metyrapone, phenelzine, doxorubicin, troleandomycin, cyclobenzaprine, erythromycin, cocaine, furafylline, cimetidine, dextromethorphan). Exceptions may be made for subjects that have received 3 days or less of one of these drugs or substances, if there has been a wash-out period equivalent to at least 5 half-lives of that drug or substance.
  20. Use of any therapeutic agents within 30 days prior to dosing known to alter any major organ function (e.g., barbiturates, opiates, phenothiazines, cimetidine).
  21. Use of systemic glucocorticoids within three months prior to dosing.
  22. HIV infection with helper/inducer T lymphocyte (CD4 cell) count of 250 10-6/L.
  23. Receiving antiretroviral therapy (ART).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01218217


Locations
South Africa
TASK Applied Sciences
Cape Town, South Africa
University of Cape Town
Cape Town, South Africa
Sponsors and Collaborators
Michael Hoelscher
Sequella, Inc.
European and Developing Countries Clinical Trials Partnership (EDCTP)
German Federal Ministry of Education and Research
Quintiles, Inc.
CMed Technologies Inc.
PathCare
Parexel
Investigators
Study Chair: Michael Hoelscher, MD Klinikum of the University of Munich
Principal Investigator: Andreas Diacon, MD Task Applied Sciences
Principal Investigator: Rodney Dawson, MD University of Cape Town

Responsible Party: Michael Hoelscher, Professor, Ludwig-Maximilians - University of Munich
ClinicalTrials.gov Identifier: NCT01218217     History of Changes
Other Study ID Numbers: LMU-IMPH-SQ109-01
First Posted: October 11, 2010    Key Record Dates
Last Update Posted: January 14, 2013
Last Verified: January 2013

Keywords provided by Michael Hoelscher, Ludwig-Maximilians - University of Munich:
TB
Tuberculosis
EBA
Pulmonary
Early Bactericidal Activity

Additional relevant MeSH terms:
Tuberculosis
Tuberculosis, Pulmonary
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Rifampin
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers